Gamo Francisco-Javier
Drug Discov Today Technol. 2014 Mar;11:81-88. doi: 10.1016/j.ddtec.2014.03.002.
Malaria is one of the world’s most deadly infectious diseases. Millions of lives are threatened by the continued development of resistance in the malaria parasite which is overcoming the effectiveness of current anti- malarial treatments. The scientific community is facing this challenge by developing new and superior therapies to combat, and potentially eradicate, this wide spread plague. New anti-Plasmodium agents derived from phe- notypic screening hits (e.g. spiroindolones) or from target based projects (e.g. DSM265) have recently entered into clinical development and hopefully will provide soon a new wave of antimalarial treatments.
疟疾是世界上最致命的传染病之一。疟原虫耐药性的持续发展正威胁着数百万人的生命，这种耐药性正在使当前抗疟治疗失效。科学界正通过研发新的、更有效的疗法来应对这一挑战，以对抗并有可能根除这种广泛传播的疫病。最近，从表型筛选所得活性物质（如螺吲哚酮）或基于靶点的项目（如DSM265）中获得的新型抗疟原虫药物已进入临床开发阶段，有望很快带来新一轮的抗疟治疗方法。
